179 results about "Consumption alcohol" patented technology

The present invention is directed to a combination treatment of an opioid antagonist e.g., naltrexone and a second compound selected from the group consisting of a GABA B agonist, an NMDA antagonist, a serotonin antagonist, and a cannabinoid antagonist is the key to the successful treatment of a brain reward system disorder. A brain reward system, include but are not limited, to pathological gambling, compulsive alcohol consumption, compulsive over-eating and obesity, compulsive smoking, and drug addiction. The compounds and methods of the present invention effectively reduce the cravings, withdrawal symptoms and negative drug side effects associated with a monotherapy. As such, patient compliance is greatly increased, thereby decreasing relapse of a brain reward system disorder.

Various embodiments of the present inventions are related to monitoring physical characteristics of a monitored individual including, but not limited to, alcohol consumption by the monitored individual.

The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.

The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention relates the use of drugs in conjunction with behavioral intervention to treat alcohol-related diseases and disorders as well as treatment of obesity and regulating weight.

The present invention relates to a composition comprising about 0.001% to about 1% by weight of cannabinoids or derivatives thereof, based on the total weight of the mixture, and an alcohol, with water and other compositions as the balance of the weight. The present invention also relates to an alcoholic beverage containing between about 0.001% to about 1% (wt / wt) cannabinoids and derivatives thereof, between about 2% to about 45% (wt / wt) of alcohol, with water, fermentation byproducts, emulsifiers, and flavor enhancers composing the balance of the total weight. The invention also discloses methods to prepare these compositions, and methods of use to minimize adverse effects from alcohol consumption.

The present invention discloses preparation process and use of Chinese paris rhizome total saponin as the effective component. The preparation process of the present invention is one simplified one comprising alcohol extraction, water precipitation, and deionized water washing and depositing. The preparation process has lowered alcohol consumption, obviously reduced production cost, no use of acetone, high effective component yield, high product purity and stable quality. The present invention also relates to the application of Chinese paris rhizome total saponin in preparing externally applied medicine for diminishing inflammation, eliminating swelling and relieving pain, antiviral medicine, and anti-tumor medicine.

Disclosed are a method for determining whether a person is drunk after consuming alcohol on the basis of a difference among a plurality of formant energy energies, which are generated by applying linear predictive coding according to a plurality of linear prediction orders, and a recording medium and a terminal for carrying out the method. The alcohol consumption determining terminal comprises: a voice input unit for receiving voice signals and converting same into voice frames and outputting the voice frames; a voiced / unvoiced sound analysis unit for extracting voice frames corresponding to a voiced sound from among the voice frames; an LPC processing unit for calculating a plurality of formant energy energies by applying linear predictive cording according to the plurality of linear prediction orders to the voice frames corresponding to the voiced sound; and an alcohol consumption determining unit for determining whether a person is drunk after consuming alcohol on the basis of a difference among the plurality of formant energy energies which have been calculated by the LPC processing unit, thereby determining whether a person is drunk after consuming alcohol depending on a change in the formant energy energies generated by applying linear predictive coding according to the plurality of linear prediction orders to voice signals.

The invention provides methods for diagnosing, assessing or quantitating drug use, drug abuse or narcosis or for differentiating drug use, drug abuse or narcosis from brain injury in a subject by tracking eye movement of at least one eye of the subject, analyzing eye movement of at least one eye of the subject, comparing eye movement of at least one eye of the subject the normal or mean eye movement; and, optionally calculating a standard deviation or p value for eye movement of at least one eye of the subject as compared to the normal or mean eye movement.

The present invention relates to (−)-1-(3,4-dichlorophenyl )-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In certain embodiments the methods and compositions of the invention are effective for treating attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, and / or an addictive disorder. In more detailed embodiments, methods and compositions of the invention are provided for treating an alcohol-related addictive disorder, for example alcohol abuse, alcohol dependence, excess alcohol consumption, and / or alcohol withdrawal. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof may be employed within the methods and compositions of the invention in a form or composition that is substantially free of its corresponding (+)-enantiomer.

The present invention is directed to the production of PKC isozyme epsi (PKCepsi)-deficient cells and non-human animals. The present invention is further directed to the identification of PKCepsi as a target for drugs that reduce anxiety. According to the present invention, PKCepsi-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKCepsi to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKCepsi, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors. Additional aspects of the present invention are diagnostic methods for identifying individuals at risk for becoming alcoholics or abusers of other drugs and kits for performing such diagnostic methods. The present invention relates to: cells and non-human animals deficient for the PKC isozyme epsi (PKCepsi); the use of PKCepsi as a target for drugs; the use of inhibitors of PKCepsi in methods of reducing anxiety and treating conditions associated with insufficient activity of the GABAA receptor; the use of modulators of PKCepsi in methods of modulating alcohol consumption, modulating self-administration of other drugs of abuse, and altering the effects of alcohol; pharmaceutical compositions comprising inhibitors of PKCepsi and allosteric agonists of GABAA receptors; and the identification of individuals with enhanced susceptibility to alcoholism or other forms of addiction.

Described is a composition for the prevention and treatment of symptoms associated with ethyl alcohol consumption. The composition comprises silymarin, salicin, at least one B vitamin, magnesium, molybdenum and manganese. Treatment of symptoms associated with the consumption of ethyl alcohol involves ingesting the described composition prior to, during, or after the consumption of the alcohol.

An embodiment of the invention belongs to the technical field of healthcare products and discloses a composition for dispelling effects of alcohol and protecting the liver and a preparation method of the composition. The composition for dispelling the effects of alcohol and protecting the liver is prepared from, by weight, 50-150 parts of rhizoma curcumae longae, 50-150 parts of fructus phyllanthi, 50-150 parts of medicine terminalia fruits and 50-150 parts of olives, wherein the rhizoma curcumae longae has an anti-inflammatory function, a liver protection function and a cholagogue effect; the fructus phyllanthi and the medicine terminalia fruits have liver protection effects and are capable of realizing reduction of liver injuries and realizing an anti-liver fibrosis function; polyphenols in the olives have functions of blood purifying, liver soothing, stomach harmonizing and qi regulating and are capable of effectively alleviating symptoms such as headache, dizziness, stomachache, nausea, poor mental state and the like caused by alcohol consumption. Choleresis increasing and gallbladder contract promoting functions of the rhizoma curcumae longae and lipid metabolism promotion and gastrointestinal peristalsis promotion functions of the olives promote liver protection functions of the fructus phyllanthi and the medicine terminalia fruits, and remarkable healthcare effects of dispelling the effects of alcohol and protecting the liver are achieved owing to synergistic interaction of the four ingredients. The preparation method of the composition is suitable for industrial popularization and application.

A composition for the prevention and treatment of symptoms (for example, a hangover) associated with ethyl alcohol consumption. The composition may comprise a gingerol, a silymarin, a catechin, and a group B vitamin. Treatment of symptoms associated with the consumption of ethyl alcohol may comprise administration of the composition prior to, during, or after the consumption of the alcohol.

Alcoholism, and symptoms and negative effects thereof may be treated using ibudilast or a pharmaceutically acceptable salt thereof. Abstinence from alcohol consumption may be maintained using ibudilast or a pharmaceutically acceptable salt thereof. Withdrawal from alcohol may be facilitated and negative effects thereof reduced by using ibudilast or a pharmaceutically acceptable salt thereof.

The invention provides a novel preparation method for natural taurine. The novel preparation method comprises the following steps: collecting an aquatic product water extract, concentrating the aquatic product water extract, obtaining precipitates and liquid supernatant after adding alcohol, and concentrating the liquid supernatant after extracting the liquid supernatant; putting the obtained concentrated liquor to crystallize under a low-temperature environment to obtain a taurine crude product; re-crystallizing the taurine crude product to obtain a wet fine product, and drying the wet fine product to obtain a finished product. The novel preparation method aims to overcome the problems that raw materials for preparing the natural taurine by a current biological extraction method are less in source and relatively high in price, overcome the problems that a process for preparing the natural aurine by adopting a conventional ion exchange method is complex in process, needs large-scale equipment, is high investment, high in cost and large in environmental pollution, and overcome the defects that a current simple prperation method for preparing the natural taurine is large in alcohol consumption amount and relatively difficult to realize industrialization.

A soft drink and method of producing a soft drink that is a fortified, normally zero calorie beverage, formulated with natural flavors such as lemon or berry that can be formulated from L-Gluamine, sodium bicarbonate, a potassium salt like potassium chloride or potassium gluconate, caffeine with optional B vitamins, folic acid and vitamin C added for fortification along with a sweetener. This drink mixture can help reduce or eliminate symptoms of a hangover caused by alcohol consumption as well as supply a large portion of the recommended daily requirements for some vitamins and minerals.

Various embodiments of the present inventions are related to monitoring physical characteristics of a monitored individual including, but not limited to, alcohol consumption by the monitored individual.

Described is a composition for the prevention and treatment of symptoms associated with ethyl alcohol consumption. The composition comprises silymarin, salicin, at least one B vitamin, magnesium, molybdenum and manganese. Treatment of symptoms associated with the consumption of ethyl alcohol involves ingesting the described composition prior to, during, or after the consumption of the alcohol.

The invention relates to the technical field of plant extraction and provides a method for extracting hesperidin from fructus aurantii immaturus according to a continuous countercurrent method and theextracted hesperidin. The method for extracting hesperidin from fructus aurantii immaturus includes: providing fructus aurantii immaturus infiltrated by alkaline alcoholic solution, mixing with alkaline alcoholic solution, performing continuous countercurrent extraction, and crystallizing extract liquid obtained in continuous countercurrent extraction to obtain hesperidin. The method is high in extraction efficiency, extraction time can be effectively shortened, and accordingly productivity is improved; in addition, extraction solvent quantity can be effectively decreased, and accordingly alcohol consumption and alcohol recovery energy consumption are sharply reduced, and cost reduction is realized; moreover, the extract liquid is high in product concentration, concentration difference ofextract liquid in different time periods is avoided, and stable product quality is realized after crystallization. The hesperidin is obtained by application of the method for extracting hesperidin from fructus aurantii immaturus. The hesperidin has advantages of high purity and quality stability and is high in market value and worthy of popularization and application.

The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms.The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active principle (AP), characterized in that it is resistant to immediate dumping of the dose of AP in the presence of alcohol. In particular, the oral form according to the invention is characterized in that the time taken to release 50% of the AP in an alcoholic solution is not reduced more than 3-fold relative to the time taken to release 50% of the AP in an alcohol-free aqueous medium.The form comprises an agent 13, which is a pharmaceutically acceptable compound whose hydration or solvation rate or capacity is greater in an alcohol-free aqueous medium than in alcoholic solution.

The present invention discloses process of preparing biodiesel oil in high efficiency. The preparation process includes the following steps: A. heating grease in a reactor; B. adding acid catalyst via heating and stirring, introducing excessive pure low carbon alcohol vapor into the reaction liquid continuously, condensing the volatilized gas and returning the condensate to the reactor for reuse; C. adding excessive alkaline catalyst, heating and stirring; and D. separating the reaction product to obtain coarse glycerin and biodiesel oil. The process has ultimate biodiesel oil conversion rate up to 98 %, high catalytic efficiency, few impurity, low alcohol consumption and short preparation period of about 4 hr.

The invention discloses a method for inspecting the detection accuracy of an animal respiratory calorimetry system, which comprises the following steps: accurately weighing an alcohol lamp, wherein an appropriate amount of anhydrous alcohol is filled in the alcohol lamp; putting the alcohol lamp into a test chamber of a respiratory calorimetry system to be detected, and igniting the alcohol lamp to start a compensation test of the system; recording the start time and the internal and external temperatures, humidities and atmospheric pressures of the test chamber; after the system runs four operating cycles, extinguishing the alcohol lamp to complete the test; recording the end time, and weighing the alcohol lamp; and finally, according to the data acquired by the system, such as gas concentration, air mass flow, anhydrous alcohol consumption, burning time and the like, calculating the recovery ratios of carbon dioxide and oxygen, and then judging the detection accuracy of the animal respiratory calorimetry system. In the method disclosed by the invention, through burning the anhydrous alcohol, an animal respiratory test is simulated so as to rapidly and accurately assess the accuracy of detection results of the animal respiratory calorimetry system, thereby providing an important method and a technical means for the development of the verification test of the system.

D-glyceric acid has been found to enhance alcohol metabolism and thereby prevent adverse effects of alcohol consumption. D-glyceric acid is administered concurrently with alcohol, to accelerate the elimination of the alcohol from the body. D-glyceric acid is converted into D-glyceraldehyde and further into glycerol in reactions catalysed by NADH-aldehyde dehydrogenase and NADH-alcohol dehydrogenase complexes, which are produced in excess during alcohol oxidation, in the cells of alcohol-metabolising tissues. In these reactions, the NADH complexes become NAD-aldehyde dehydrogenase and NAD-alcohol dehydrogenase complexes. These complexes in turn accelerate the oxidation of alcohol, which is paralleled by enhancement of acetaldehyde oxidation to metabolically harmless acetic acid. D-glyceric acid or its salt or ester is used for the manufacture of a pharmaceutical preparation for enhancing the metabolism of alcohol. A method of enhancing the metabolism of alcohol in a subject by administering said compounds an effective amount of D-glyceric acid or its salt or ester is disclosed. An oral or parenteral preparation comprising said compounds is also disclosed.

Disclosed are compositions and methods for reducing blood alcohol content following alcohol consumption. The inventive compositions and methods rapidly reduce blood alcohol content and alleviate symptoms of intoxication in a subject having an elevated blood alcohol content due to alcohol consumption.

Disclosed are a method for determining whether a person is drunk after consuming alcohol capable of analyzing alcohol consumption in a time domain by analyzing a voice, and a recording medium and a terminal for carrying out same. An alcohol consumption-determining terminal comprises: a voice input unit for generating a voice frame by converting an inputted voice signal and outputting the voice frame; a voiced / unvoiced sound analysis unit for determining whether the voice frame inputted through the voice input unit corresponds to a voiced sound, an unvoiced sound, or background noise; a voice frame energy detection unit for extracting the average energy of voice frames which have been determined as a voiced sound by the voiced / unvoiced sound analysis unit; an interval energy detection unit for detecting the average energy of intervals including a plurality of voice frames which have been determined as voiced sounds; and an alcohol consumption determining unit for determining whether a person is drunk after consuming alcohol by extracting a difference value among the average energy of neighboring intervals which have been detected by the interval energy detection unit, thereby determining whether a person is drunk after consuming alcohol by analyzing the voice signal in a time domain.

The invention discloses a clarification method of a traditional Chinese medicine preparation for treating psoriasis, which comprises adding 4% of natural clarifier B component and 2 % component A, in a water bath at 60°C, with an interval of 1h between the two components, and stirring for 1min every 0.5h, then centrifuged, and the supernatant was taken. The clarification and impurity removal method adopted in the present invention does not require any special equipment, has low equipment investment and simple operation process, and overcomes the defects of the traditional alcohol precipitation and impurity removal method, such as large alcohol consumption, time-consuming process, and cumbersome ethanol recovery process. At the same time, the results of cell experiments showed that both the traditional Chinese medicine preparation for the treatment of psoriasis and the unmodified Yinxie Ling Fang had the effect of inhibiting the proliferation of keratinocytes. The taste of the medicine was simplified and reasonable, and it was less toxic than the chemical drug methotrexate.

A device for managing alcohol consumption of a user includes a camera that captures an image associated with a beverage container, a display unit, a memory unit that stores (a) a set of modules, and (b) a database, and (iv) a processor that executes (a) an alcohol content identification module, when executed by the processor, identifies (i) a type of drink in the beverage container and (ii) an alcohol content associated with the drink, (b) an alcohol consumption determination module, executed by the processor, determines an alcohol consumption by the user, (c) an alcohol consumption updating module, when executed by the processor, updates the alcohol consumption by the user in the database, and (d) an alert generation module, when executed by the processor, generates an alert when the alcohol consumption by the user is in proximity with the at least one of periodic threshold.

Accurate self report strategies, biological state markers, combinations of alternative biomarkers, and combinations of biomarkers and self reports capable of monitoring alcohol consumption with a high sensitivity and specificity over a broad time spectrum are disclosed. In particular, the use of ethyl sulfate (monoethylsulfate, molecular weight 126 g / mol, C2H5SO4H) to elucidate ethanol intake is described in the context of screening monitoring in various settings, e.g. a) after liver transplantation b) methadone maintenance patients with hepatitis C and comorbid excessive alcohol use c) underage drinking d) rehabilitation programs for alcoholics motivational feedback to improve knowledge on drinking patterns differentiating moderate / social drinking from problematic / harmful drinking differential diagnosis (e.g. elevated transaminases) evaluating treatment programs and drug trials elucidating the role of neuropsychological impairment following alcoholisation (i.e. hangover state) which plays a major role in accidents, disclosing recent drinking in social drinkers in risky situations (driving, workplaces, pregnancy (fetal alcohol syndrome (FAS)), and general monitoring.

The present invention relates to methods and compositions of metadoxine and physiologically compatible active derivatives thereof, and their use for decreasing symptoms of alcohol consumption as well as in the prevention of alcohol consumption related symptoms in subjects in need thereof.

The invention relates to a method for comprehensively processing konjak by a wet method. The invention relates to the agricultural and sideline products processing technical field, and is characterized in that waste alcohol generated by processing konjak fine flour through the wet method enables standing and separating, the obtained solid object is wet ash powder; a part of the separated clarification waste alcohol is returned to a konjak fine flour processing link, another part of the separated clarification waste alcohol is used for extracting alkaloid in konjak residues, a leaching liquor enables pressure reduction and concentration, new thick alcohol enables alcohol precipitation, the separated solid object is returned to a residues alkaloid extraction operation, the liquid is concentrated to an extract to obtain crude alkaloid; the wet ash powder and the extracted residues enable pressure reduction and desolvation, and are dried to obtain dry ash powder and dry residues. The method for comprehensively processing konjak by the wet method can produce the konjak ash powder capable of being as a material for processing feed and food with the characteristics of low alkaloid content and no stench flavor, the konjak crude alkaloid and konjak residues powder (soil moisture retention material) which is harmless to plants, the alcohol consumption is little, the environmental pollution is less, the konjak utilization rate is more than 95%, and the relative processing cost is low.